Synergy between cigarette smoking and human papillomavirus type 16 in cervical cancer in situ development

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 11, 2006, Pages 2141-2147

  Gunnell, Anthony S ^a   Tran, Trung N ^a   Torrång, Anna ^a   Dickman, Paul W ^a   Sparén, Pär ^a   Palmgren, Juni ^b   Ylitalo, Nathalie ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CANCER GROWTH; CANCER RISK; CARCINOMA IN SITU; CHILD; CIGARETTE SMOKING; CONTROLLED STUDY; DRUG USE; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PRIORITY JOURNAL; RISK ASSESSMENT; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS INFECTION;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; ODDS RATIO; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; SMOKING; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD;

EID: 33845308815     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0399     Document Type: Article

References (58)

1. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol 2005;20:207-25.
2. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003;89:101-5.
3. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73.
4. Moore TO, Moore AY, Carrasco D, et al. Human papillomavirus, smoking, and cancer. J Cutan Med Surg 2001;5:323-8.
5. Haverkos HW, Soon G, Steckley SL, Pickworth W. Cigarette smoking and cervical cancer. Part I: a meta-analysis. Biomed Pharmacother 2003;57:67-77.
6. Ali S, Astley SB, Sheldon TA, Peel KR, Wells M. Detection and measurement of DNA adducts in the cervix of smokers and non-smokers. Int J Gynecol Cancer 1994;4:188-93.
7. Phillips DH, She MN. DNA adducts in cervical tissue of smokers and nonsmokers. Mutat Res 1994;313:277-84.
8. Prokopczyk B, Cox JE, Hoffmann D, Waggoner SE. Identification of tobacco-specific carcinogen in the cervical mucus of smokers and nonsmokers. J Natl Cancer Inst 1997;89:868-73.
9. Yang X, Jin G, Nakao Y, et al. Malignant transformation of HPV 16-immortalized human endocervical cells by cigarette smoke condensate and characterization of multistage carcinogenesis. Int J Cancer 1996;65:338-44.
10. Poppe WA, Ide PS, Drijkoningen MP, Lauweryns JM, Van Assche FA. Tobacco smoking impairs the local immunosurveillance in the uterine cervix. An immunohistochemical study. Gynecol Obstet Invest 1995;39:34-8.
11. Hellberg D, Valentin J, Nilsson S. Smoking and cervical intraepithelial neoplasia. An association independent of sexual and other risk factors? Acta Obstet Gynecol Scand 1986;65:625-31.
12. Phillips AN, Smith GD. Cigarette smoking as a potential cause of cervical cancer: has confounding been controlled?. Int J Epidemiol 1994;23:42-9.
13. Ho GY, Kadish AS, Burk RD, et al. HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia. Int J Cancer 1998;78:281-5.
14. Plummer M, Herrero R, Franceschi S, et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. Cancer Causes Control 2003;14:805-14.
15. Harris TG, Kulasingam SL, Kiviat NB, et al. Cigarette smoking, oncogenic human papillomavirus, Ki-67 antigen, and cervical intraepithelial neoplasia. Am J Epidemiol 2004;159:834-42.
16. McIntyre-Seltman K, Castle PE, Guido R, Schiffman M, Wheeler CM. Smoking is a risk factor for cervical intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology. Cancer Epidemiol Biomarkers Prev 2005;14:1165-70.
17. Rajeevan MS, Swan DC, Nisenbaum R, et al. Epidemiologic and viral factors associated with cervical neoplasia in HPV-16-positive women. Int J Cancer 2005;115:114-20.
18. Deacon JM, Evans CD, Yule R, et al. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer 2000;83:1565-72.
19. Castle PE, Wacholder S, Lorincz AT, et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst 2002;94:1406-14.
20. Olsen AO, Dillner J, Skrondal A, Magnus P. Combined effect of smoking and human papillomavirus type 16 infection in cervical carcinogenesis. Epidemiology 1998;9:346-9.
21. Hakama M, Luostarinen T, Hallmans G, et al. Joint effect of HPV16 with Chlamydia trachomatis and smoking on risk of cervical cancer: antagonism or misclassification (Nordic countries). Cancer Causes Control 2000;11:783-90.
22. Ylitalo N, Sorensen P, Josefsson A, et al. Smoking and oral contraceptives as risk factors for cervical carcinoma in situ. Int J Cancer 1999;81:357-65.
23. Chua KL, Hjerpe A. Polymerase chain reaction analysis of human papillomavirus in archival cervical cytologic smears. Anal Quant Cytol Histol 1995;17:221-9.
24. Ylitalo N, Sorensen P, Josefsson AM, et al. Consistent high viral load of human papiliomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 2000;355:2194-8.
25. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2005;118:1481-95.
26. Dalstein V, Riethmuller D, Pretet JL, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003;106:396-403.
27. Josefsson AM, Magnusson PK, Ylitalo N, et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 2000;355:2189-93.
28. Wu Y, Chen Y, Li L, et al. Associations of high-risk HPV types and viral load with cervical cancer in China. J Clin Virol 2006;35:264-9.
29. Moberg M, Gustavsson I, Gyllensten U. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer 2004;112:854-9.
30. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-71.
31. Wallin KL, Wiklund F, Angstrom T, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999;341:1633-8.
32. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999;354:20-5.
33. Cuschieri KS, Cubie HA, Whitley MW, et al. Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. J Clin Pathol 2005;58:946-50.
34. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005;191:182-92.
35. Schiffman M, Herrero R, Desalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005;337:76-84.
36. Giuliano AR, Sedjo RL, Roe DJ, et al. Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States). Cancer Causes Control 2002;13:839-46.
37. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235-40.
38. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;38:423-8.
39. Koshiol J, Schroeder J, Jamieson DJ, et al. Smoking and time to clearance of human papillomavirus infection in HIV-seropositive and HIV-seronegative women. Am J Epidemiol 2006;164:176-83.
40. Molano M, Van den Brule A, Plummer M, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003;158:486-94.
41. Minkoff H, Feldman JG, Strickler HD, et al. Relationship between smoking and human papillomavirus infections in HIV-infected and -uninfected women. J Infect Dis 2004;189:1821-8.
42. Sun XW, Kuhn L, Ellerbrock TV, et al. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997;337:1343-9.
43. Schiffman M, Kjaer SK. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003;31:14-9.
44. Barton SE, Maddox PH, Jenkins D, et al. Effect of cigarette smoking on cervical epithelial immunity: a mechanism for neoplastic change? Lancet 1988;2:652-4.
45. Morris HH, Gatter KC, Sykes G, Casemore V, Mason DY. Langerhans' cells in human cervical epithelium: effects of wart virus infection and intraepithelial neoplasia. Br J Obstet Gynaecol 1983;90:412-20.
46. Morelli AE, Sananes C, Di Paola G, Paredes A, Fainboim L. Relationship between types of human papillomavirus and Langerhans' cells in cervical condyloma and intraepithelial neoplasia. Am J Clin Pathol 1993;99:200-6.
47. Ronco LV, Karpova AY, Vidal M, Howley PM. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998;12:2061-72.
48. Park JS, Kim EJ, Kwon HJ, et al. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem 2000;275:6764-9.
49. Chang YE, Laimins LA. Interferon-inducible genes are major targets of human papillomavirus type 31: insights from microarray analysis. Dis Markers 2001;17:139-42.
50. Nees M, Geoghegan JM, Hyman T, et al. Papillomavirus type 16 oncogenes down-regulate expression of interferon-responsive genes and up-regulate proliferation-associated and NF-κB-responsive genes in cervical keratinocytes. J Virol 2001;75:4283-96.
51. + T-cell immunity against early antigens E2 and E6. Cancer Res 2004;64:5449-55.
52. Jacobs N, Giannini SL, Doyen J, et al. Inverse modulation of IL-10 and IL-12 in the blood of women with preneoplastic lesions of the uterine cervix. Clin Exp Immunol 1998;111:219-24.
53. Ouyang Y, Virasch N, Hao P, et al. Suppression of human IL-1β, IL-2, IFN-γ, and TNF-α production by cigarette smoke extracts. J Allergy Clin Immunol 2000;106:280-7.
54. Vassallo R, Tamada K, Lau JS, Kroening PR, Chen L. Cigarette smoke extract suppresses human dendritic cell function leading to preferential induction of Th-2 priming. J Immunol 2005;175:2684-91.
55. Kirkpatrick A, Bidwell J, van den Brule AJ, et al. TNFα polymorphism frequencies in HPV-associated cervical dysplasia. Gynecol Oncol 2004;92:675-9.
56. Deshpande A, Nolan JP, White PS, et al. TNF-α promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer. J Infect Dis 2005;191:969-76.
57. Suk K, Chang I, Kim YH, et al. Interferon γ (IFN-γ) and tumor necrosis factor α synergism in ME-180 cervical cancer cell apoptosis and necrosis. IFNβ inhibits cytoprotective NF-κ through STAT1/IRF-1 pathways. J Biol Chem 2001;276:13153-9.
58. Rosty C, Sheffer M, Tsafrir D, et al. Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. Oncogene 2005;24:7094-104.